The NAD+ Reference

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all eukaryotic cells. It is the principal electron carrier in cellular bioenergetics, cycling between its oxidised (NAD+) and reduced (NADH) forms across the citric acid cycle, glycolysis, beta-oxidation, and the electron transport chain. The molecule consists of two nucleotides, one bearing a nicotinamide base, the other bearing an adenine base, joined through their phosphate groups via a pyrophosphate linkage. The molecular mass is approximately 663.4 Da.

NAD+ is a coenzyme, not a peptide. Baseline works with it alongside the peptides, in the same pen format and on the same terms, after a consultation, but it is structurally distinct from the peptide compounds (BPC-157, MOTS-c, retatrutide, and so on) and acts through a different mechanism.

An NAD+ peptide pen is not a ballpoint pen, writing implement, or office supply, and despite the commercial naming convention NAD+ itself is not a peptide. The pen format refers to a factory-sealed, pre-filled research delivery device supplied ready to use at a fixed concentration.

NAD+ has no regulatory approval as a pharmaceutical in any jurisdiction. The compound is supplied as a research material for laboratory use only. The closely-related precursors NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) have been studied in human trials but have not received regulatory approval either.

How NAD+ differs from NMN and NR

NAD+ is the active coenzyme. NMN and NR are precursors that raise tissue NAD+ levels through the salvage pathway. NMN bypasses one enzymatic step (NAMPT) in the salvage pathway; NR is converted to NMN by nicotinamide riboside kinases (NRKs) and then to NAD+. The three compounds are studied in the same research literature because all increase the NAD+ pool, but they are distinct chemical entities.

Why NAD+ is written as NAD, NADH, or NAD plus

Four variant names and forms appear across the literature and commercial sources.

NAD+ acts through four principal pathway threads in the research literature. The first is its classical role as a redox cofactor. The other three are consumption pathways where NAD+ is the substrate for enzymatic activity, not just a recyclable electron carrier.

NAD+ and the aging biology framework

Imai and Guarente (Trends Cell Biol, 2014;24(8):464-471) reviewed the relationship between NAD+ availability, sirtuin activity, and age-related metabolic dysfunction. The published review framed declining tissue NAD+ as an Achilles' heel of cellular aging, with downstream effects on nuclear and mitochondrial function. The paper is a widely-cited entry point into the NAD+ aging-biology research field.

NMN precursor research in mouse models

Mills and colleagues (Cell Metab, 2016;24(6):795-806) reported a 12-month NMN administration study in wild-type C57BL/6N mice. The published findings reported that orally administered NMN was rapidly utilised to synthesise NAD+ in tissues, with downstream effects on body weight gain, energy metabolism, insulin sensitivity, plasma lipid profile, and age-associated gene expression changes. The work established the long-term NMN precursor research model.

NMN human trial in prediabetic postmenopausal women

Yoshino and colleagues (Science, 2021;372(6547):1224-1229) reported a 10-week randomised placebo-controlled trial of NMN supplementation (250 mg/day) in postmenopausal women with prediabetes. The published findings reported increased skeletal muscle insulin signalling and insulin sensitivity in the NMN arm, with elevated NAD+ levels in peripheral blood mononuclear cells. The work is the most commonly cited human NMN trial.

All effects described in this section have been observed in published research. Findings on NMN do not directly translate to claims about NAD+ supplementation; the two are distinct compounds in distinct pharmacokinetic contexts. The Mills and Yoshino work is referenced here for research context.

References

The three primary peer-reviewed sources referenced in this guide. The originals are linked in full for anyone who wants the methods behind them.

• Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. doi:10.1016/j.tcb.2014.04.002.
• Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. doi:10.1016/j.cmet.2016.09.013.
• Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985.

NAD+ appears across four principal research application areas in the published literature. The compound's role as a fundamental coenzyme means it touches a much broader literature than any peptide; the four areas below are the ones where NAD+ is studied as a direct or indirect intervention.

Cellular bioenergetics research

The classical research application area. Investigators studying mitochondrial function, the electron transport chain, and the relationship between NAD+/NADH ratio and metabolic state use NAD+ as a research tool. This area predates the sirtuin literature by decades and remains active.

Sirtuin pathway and aging biology research

The most heavily published modern application area. The Imai and Guarente 2014 review provides a widely-cited research entry point. Investigators use NAD+ and its precursors as research tools to probe sirtuin activity, the relationship between NAD+ availability and SIRT1-SIRT7 function, and age-related cellular dysfunction.

DNA damage and PARP substrate research

Poly-ADP-ribose polymerases (PARPs) consume NAD+ during DNA damage repair. Investigators studying genomic stability, oncology research, and the balance between sirtuin and PARP NAD+ consumption use NAD+ as a substrate research tool.

Precursor pathway research (NMN, NR)

The Mills 2016 mouse paper and the Yoshino 2021 human paper anchor the precursor research literature. Investigators studying NMN and NR pharmacokinetics, salvage-pathway dynamics, and tissue NAD+ replenishment use NAD+ as the downstream measurement target. Baseline consultants work with NAD+ directly, not the precursors.

A research pen is a factory-sealed, pre-filled delivery device supplied ready to use at a fixed concentration, with no reconstitution or mixing step at the point of use. The format originated in clinical injection devices and has been adapted for research handler use where dose consistency across experiments matters more than per-experiment flexibility.

For NAD+ specifically, the pen format addresses a real property of the molecule: NAD+ in solution is comparatively unstable and oxidation-sensitive. A factory-sealed pre-filled pen keeps the solution protected from the air exposure and handling that accelerate that breakdown, particularly across the GCC summer months when ambient temperature management is challenging.

A pen fixes the concentration set at manufacture, which suits a single-concentration study or a series of replicates at the same dose and reduces handler variance. For in vitro assays that call for a range of working concentrations, researchers derive those from the fixed-concentration stock in the laboratory.

The Baseline NAD+ research pen is supplied at a fixed concentration with batch-specific HPLC purity and mass spectrometry confirmation on the CoA.

The quality of NAD+ is defined by the documentation that accompanies it. A coenzyme with a published synthesis route but no batch-specific Certificate of Analysis is not a research material; it is an unknown. NAD+ is particularly demanding because of its oxidation sensitivity, so the CoA should document not just purity but stability handling.

• HPLC purity greater than 98 percent, ideally above 99 percent for sensitive research applications.
• Mass spectrometry confirmation of the NAD+ molecular mass (663.4 Da).
• Documented batch concentration and stability information.
• Batch-specific Certificate of Analysis from an independent third-party lab, not just an in-house result.
• Endotoxin testing where the material is intended for cell culture or animal research.
• Documented cold-chain handling from synthesis through shipping, with temperature logs available on request.

For Baseline NAD+, the per-batch lab report is published at /uae/peptides/nad-1000. The CoA documents HPLC purity, mass spectrometry confirmation of the NAD+ molecular mass, and the in-house concentration assay. Independent third-party reports are available on request.

If there is no CoA, there is no compound. Only powder.

Research compounds are not pharmaceuticals under UAE Federal Decree-Law No. 38 of 2024 and are not regulated as medicines. NAD+ is not an approved medicine and is only ever considered after a consultation. Your consultant reviews your history first, and you are monitored throughout.

The UAE has emerged as a regional hub for research compound supply, partly because of the climate-driven cold-chain expertise developed across the GCC pharmaceutical distribution network. NAD+ is particularly sensitive to cold-chain integrity because of its oxidation sensitivity in solution. See peptide delivery and GCC cold chain for the operational considerations.

For the full UAE regulatory context covering research compound procurement, see Is it legal to buy peptides in Dubai and the UAE.

The questions below cover the most common queries from UAE-based researchers and procurement teams. Each answer is independently sourced and can be cross-referenced against the linked product pages and lab results.

NAD+ is one of several compounds Baseline consultants work with, each documented the same way. The references below provide background on adjacent research compounds frequently studied alongside NAD+.

See how it sits against the other longevity compounds we work with in the UAE.